Kotak Mahindra Bank Standalone PAT For Q4FY26 At ₹ 4,027 Crore, Up 13% YoY And 17% QoQ

* Standalone PAT for FY26 at ₹ 14,008 crore

* Consolidated PAT for Q4FY26 at ₹ 5,423 crore, up 10% YoY and 10% QoQ Consolidated PAT for FY26 at ₹ 19,288 crore

The Board of Directors of Kotak Mahindra Bank (“the Bank”) approved the audited standalone and consolidated results for the quarter and financial year ended March 31, 2026, at the Board meeting held in Mumbai, today.

Kotak Mahindra Bank standalone results

The Bank’s PAT for Q4FY26 increased to ₹ 4,027 crore, up 13% YoY from ₹ 3,552 crore in Q4FY25 (up 17% QoQ from ₹ 3,446 crore in Q3FY26). PAT for FY26 stood at ₹ 14,008 crore, up 2% YoY from ₹ 13,720 crore in FY25 (excluding gain on ZKGI divestment).

Net Interest Income (NII) for Q4FY26 increased to ₹ 7,876 crore, up 8% YoY from ₹ 7,284 crore in Q4FY25 (up 4% QoQ from ₹ 7,565 crore in Q3FY26) and for FY26 increased to ₹ 30,010 crore, up 6% YoY from ₹ 28,342 crore in FY25.

Net Interest Margin (NIM) was 4.67% for Q4FY26 (4.97% for Q4FY25 and 4.54% for Q3FY26). NIM was 4.60% for FY26 (4.96% for FY25).

Cost of funds was 4.45% for Q4FY26 (5.09% for Q4FY25 and 4.54% for Q3FY26). Cost of funds was 4.67% for FY26 (5.10% for FY25).

Fees and services for Q4FY26 increased to ₹ 2,767 crore, up 6% YoY from ₹ 2,616 crore in Q4FY25 (up 9% QoQ from ₹ 2,549 crore in Q3FY26) and for FY26 increased to ₹ 9,981 crore, up 5% YoY from ₹ 9,530 crore in FY25.

Operating expenses for Q4FY26 increased to ₹ 5,137 crore, up 3% YoY from ₹ 4,994 crore in Q4FY25 (up 2% QoQ from ₹ 5,023 crore in Q3FY26) and for FY26 increased to ₹ 19,566 crore, up 4% YoY from ₹ 18,754 crore in FY25. Cost to assets was 2.73% for Q4FY26 and 2.75% for FY26.

Operating profit for Q4FY26 increased to ₹ 5,855 crore, up 7% YoY from ₹ 5,472 crore in Q4FY25 (up 9% QoQ from ₹ 5,380 crore in Q3FY26) and for FY26 increased to ₹ 22,067 crore, up 5% YoY from ₹ 21,006 crore in FY25.

Provisions for Q4FY26 decreased to ₹ 516 crore, down 43% YoY from ₹ 909 crore in Q4FY25 (down 36% QoQ from ₹ 810 crore in Q3FY26) and for FY26 was ₹ 3,481 crore (₹ 2,942 crore for FY25). Credit cost (annualised) for Q4FY26 stood at 0.39% (0.64% for Q4FY25 and 0.63% for Q3FY26) and for FY26 stood at 0.65% (0.60% for FY25).

Net Advances increased 16% YoY to ₹ 496,009 crore as at March 31, 2026 from ₹ 426,909 crore as at March 31, 2025. Customer Assets which comprise Advances (incl. IBPC & BRDS) and Credit Substitutes grew to ₹ 545,716 crore as at March 31, 2026, up 14% YoY from ₹ 477,855 crore as at March 31, 2025.

Total period-end Deposits grew to ₹ 572,456 crore for Q4FY26, up 15% YoY from ₹ 499,055 crore for Q4FY25. Average Total Deposits grew to ₹ 538,301 crore for Q4FY26, up 15% YoY from ₹ 468,486 crore for Q4FY25.

Average Current Deposits grew to ₹ 77,058 crore for Q4FY26, up 18% YoY from ₹ 65,427 crore for Q4FY25. Average Fixed rate Savings Deposits grew to ₹ 122,364 crore for Q4FY26, up 17% YoY from ₹ 104,379 crore for Q4FY25.

Average Term Deposits grew to ₹ 326,403 crore for Q4FY26, up 16% YoY from ₹ 280,448 crore for Q4FY25. CASA ratio as at March 31, 2026 stood at 43.3% (43.0% as at March 31, 2025).

Credit to Deposit ratio as at March 31, 2026 stood at 86.6% (85.5% as at March 31, 2025).

Customers as on March 31, 2026 were 5.2 crore.

Slippages for Q4FY26 decreased to ₹ 1,018 crore, down 32% YoY from ₹ 1,488 crore in Q4FY25. As at March 31, 2026, GNPA was 1.20% & NNPA was 0.25% (GNPA was 1.42% & NNPA was 0.31% as at March 31, 2025).

As at March 31, 2026, Provision Coverage Ratio stood at 79% (78% as at March 31, 2025).

Standalone Return on Assets (ROA) for Q4FY26 (annualised) was 2.14% and for FY26 was 1.97%. Return on Equity (ROE) for Q4FY26 (annualised) was 12.27% and for FY26 was 11.08%.

Capital Adequacy Ratio of the Bank, as per Basel III, as at March 31, 2026 was 22.4% and CET1 ratio of 21.3%. The Board of Directors of the Bank has recommended dividend of ₹ 0.65 per equity share having face value of ₹ 1, for the year ended March 31, 2026, subject to approval of shareholders.

Consolidated results at a glance

Consolidated PAT for Q4FY26 stood at ₹ 5,423 crore, up 10% YoY from ₹ 4,933 crore in Q4FY25 (up 10% QoQ from ₹ 4,924 crore in Q3FY26) and for FY26 stood at ₹ 19,288 crore.

Excluding gain of ₹ 185 crore on Infina Finance Private Limited (“Infina”) divestment after considering its carrying value in consolidated financials, PAT for Q4FY26 stood at ₹ 5,238 crore, up 6% YoY and 6% QoQ and for FY26 stood at ₹ 19,103 crore (₹ 19,113 crore in FY25 excluding gain on ZKGI divestment).

PAT of Bank and key subsidiaries given below:

 

PAT (₹ crore)		Q4FY26		Q4FY25		Q3FY26		FY26		FY25
Kotak Mahindra Bank		4,027		3,552		3,446		14,008		13,7201
Kotak Securities		400		348		431		1,642		1,640
Kotak Mahindra Prime		240		297		250		1,008		1,015
Kotak Asset Management & Trustee Company		184		364		315		1,082		977
Kotak Mahindra Investments		115		116		87		428		501
Kotak Mahindra Capital		103 2		96		98		350 2		361
Kotak Mahindra Life Insurance		90		73		162		628		769
Kotak Alternate Asset Managers		54		101		75		292		139

1. FY25 Kotak Mahindra Bank PAT excluding gain on ZKGI divestment

2. Q4FY26 & FY26 Kotak Mahindra Capital PAT does not include gains of ₹ 1,094 crore on divestment of stake in its associate, Infina.

Consolidated Customer Assets which comprise Advances (incl. IBPC & BRDS) and Credit Substitutes grew to ₹ 616,219 crore as at March 31, 2026, up 15% YoY from ₹ 537,860 crore as at March 31, 2025.

Customer Assets Under Management as at March 31, 2026 grew to ₹ 747,613 crore, up 12% YoY from ₹ 667,163 crore as at March 31, 2025. The total Domestic MF AUM increased by 16% YoY to ₹ 555,230 crore as at March 31, 2026.

Consolidated Networth as at March 31, 2026 was ₹ 181,113 crore. The Book Value per Share increased to ₹ 182 as at March 31, 2026, up 15% YoY from ₹ 158 as at March 31, 2025 (computed based on subdivision of 1 equity share of face value of ₹ 5 each into 5 equity shares of ₹ 1 each with effect from 14th January, 2026).

At the consolidated level, Return on Assets (ROA) for Q4FY26 (annualized) was 2.18% and for FY26 was 2.06%. Return on Equity (ROE) for Q4FY26 (annualized) was 11.92% and for FY26 was 11.28%. Q4FY26 and FY26 ROA and ROE are excluding gains of ₹ 185 crore on Infina divestment.

Consolidated Capital Adequacy Ratio as per Basel III as at March 31, 2026 was 23.0% and CET I ratio was 22.1%.

Consolidated Average Liqudity Coverage Ratio stood at 134% for Q4FY26.

About Kotak Mahindra Group

Established in 1985, Kotak Mahindra Group is one of India's leading financial services conglomerates. In February 2003, Kotak Mahindra Finance Ltd. (KMFL), the Group's flagship company, received banking license from the Reserve Bank of India (RBI), becoming the first non-banking finance company in India to convert into a bank - Kotak Mahindra Bank Ltd (KMBL).

Kotak Mahindra Group (Group) offers a wide range of financial services that encompass every sphere of life. From commercial banking, to stock broking, mutual funds, life and general insurance and investment banking, the Group caters to the diverse financial needs of individuals and the corporate sector. The premise of Kotak Mahindra Group’s business model is concentrated India, diversified financial services. The bold vision that underscores the Group’s growth is an inclusive one, with a host of products and services designed to address the needs of the unbanked and insufficiently banked.

Kotak Mahindra Group has a global presence through its subsidiaries in UK, USA, Gulf Region, Singapore and Mauritius with offices in London, New York, Dubai, Abu Dhabi, Singapore and Mauritius respectively. As on 31st March, 2026, Kotak Mahindra Bank Ltd has a national footprint of 2,276 branches and 2,727 ATMs (incl. cash recyclers), and branches in GIFT City and DIFC (Dubai).

For more information, visit the Company’s website at https://www.kotak.com

Air India Lands At Hanoi, Beginning Services To Its Second Gateway In Vietnam

Air India has inaugurated its new 5x weekly non-stop service to Hanoi, touching down at the Vietnamese capital city for the first time. Hanoi is Air India’s second gateway in Vietnam after Ho Chi Minh City and the eighth destination in Southeast Asia.

Flight AI2390 departed from Delhi at 0120 Hrs (IST), landing at Noi Bai International Airport at 0720 Hrs (local time), where it was welcomed by dignitaries from the Indian Embassy in Vietnam, airport officials, and Air India staff.

The new five times weekly service complements Air India’s daily flights to Ho Chi Minh City, offering travellers greater flexibility to explore Vietnam with open-jaw itineraries. With the launch of this service, travellers can conveniently arrive in Hanoi and return from Ho Chi Minh City, or vice versa, making multi-city leisure and business travel easier.

Air India’s Delhi-Hanoi service is operated by Air India’s A320neo aircraft, featuring a three-class cabin configuration including Business Class, Premium Economy and Economy, delivering a premium, full-service flying experience to and from India and beyond.

The new service also seamlessly connects points in the United Kingdom and Europe to Vietnam, enabling travellers between these regions to travel conveniently via Air India’s hub at Delhi.

Nipun Aggarwal, Chief Commercial Officer, Air India, said: “Vietnam has rapidly evolved into a high-potential market for Indian travellers, supported by strong leisure demand, growing business exchanges and rising interest in multi-city holidays. With Hanoi joining our network alongside Ho Chi Minh City, we are creating more choice, greater convenience and stronger connectivity between the two countries as well as enabling traffic between Europe and Vietnam.”

SCHEDULE OF FLIGHTS BETWEEN DELHI (DEL) AND HANOI (HAN)
FLIGHT #	CITY PAIR	DEPARTURE	ARRIVAL	DAYS OF OPERATION
AI2390	Delhi - Hanoi	0120 hrs	0720 hrs	Mon, Wed, Fri, Sat and Sun
AI2391	Hanoi - Delhi	0820 hrs	1135 hrs	Mon, Wed, Fri, Sat and Sun

Bookings are available via travel agents worldwide and will be progressively opened on Air India’s website (www.airindia.com) and mobile app.

About Air India group

The Air India group – comprising full-service global airline, Air India, and value carrier, Air India Express – is spearheading a new era of Indian aviation. The Air India story began in 1932 when JRD Tata piloted the airline’s inaugural flight and opened the skies for aviation in India. Today, Air India group employs more than 30,000 people, operates over 300 aircraft and carries travellers to 60 domestic and 51 international destinations across five continents.

Returning to Tata Sons in 2022 following 70 years under Government ownership, Air India group is in the midst of a five-year transformation programme, Vihaan.AI. As part of the transformation, Air India has placed orders for 600 new aircraft. In addition to taking new aircraft deliveries, Air India is progressively retrofitting all its legacy aircraft.

The Air India group operates South Asia’s largest aviation training academy in Gurugram, India. The construction of a new flying school and a greenfield maintenance base is in progress. With transformation underway across all facets of the business and India’s rich legacy of hospitality, Air India is committed to being a world-class global airline with an Indian heart.

For more news on Air India, visit http://www.airindia.com/newsroom  

Tata Motors Registered 28% Growth YoY With Total Sales Of 34,833 Commercial Vehicle Units In April 2026

Tata Motors Limited sales in the domestic & international markets for April 2026 stood at 34,833 units, compared to 27,221 units during April 2025, up 28% YoY.

 

Category	April 2026	April 2025	Growth  (Y-o-Y)
HCV Trucks	8,969	7,270	23.4%
ILMCV Trucks	5,454	4,680	16.5%
Passenger Carriers	5,743	4,683	22.6%
SCV cargo and pickup	12,799	9,131	40.2%
Domestic Sales	32,965	25,764	27.9%
International Business	1,868	1,457	28.2%
Total	34,833	27,221	28.0%

 

Domestic sales of MH&ICV in April 2026, was 14565 units vs 12093 units in April 2025.

Domestic & International sales for MH&ICV in April 2026, was 15403 units vs 12760 units in April 2025.

About Tata Motors Ltd (Formerly TML Commercial Vehicles Ltd):

Part of the USD 180 billion Tata Group, Tata Motors Ltd., (BSE: Scrip code 544569; NSE: Scrip code TMCV) is India’s largest and a globally renowned manufacturer of utility vehicles, pick-ups, trucks, and buses. With over eight decades of leadership in commercial mobility, the company is known for its innovation, reliability, and performance. Its advanced powertrains, connected technologies, and intelligent fleet solutions support a wide range of applications—from last-mile delivery to public transport while seamlessly driving the wheels of the nation’s economy. Guided by its brand promise Better Always, Tata Motors delivers future-ready solutions that enhance customer experience and drive sustainable growth. The company operates in India and South Korea, with a global presence across Africa, the Middle East, Latin America, Southeast Asia, and SAARC countries.

As per the Composite Scheme of Arrangement sanctioned by the Hon’ble National Company Law Tribunal, Mumbai Bench—amongst Tata Motors Limited, TML Commercial Vehicles Limited (the Company) and Tata Motors Passenger Vehicles Limited—the Company’s name was changed to Tata Motors Limited from TML Commercial Vehicles Limited (effective 29 October 2025), and its equity shares are listed on the BSE Ltd and the National Stock Exchange of India Limited.

Experience Every Super Moment This Cricket Season With California Almonds

Introducing Superfood for a Super You — a bold, new brand platform brought to life through an exciting campaign featuring famous cricket personality Navjot Singh Sidhu, whose signature energy invites fans to engage, celebrate, and win big.

This cricket season, California Almonds brings together the excitement of cricket with the nutritional power of almonds, through its latest campaign, ‘Superfood for a Super You’. Packed with 24 nutrients, including vitamin E, fibre, magnesium, protein; almonds are the ultimate superfood, and can help support sustained energy and performance, both on and off the cricket field.

At the heart of the campaign is a mobile-first interactive contest that invites participants across India to couple the excitement of live cricket, with the discovery of almond benefits in a fun, immersive way. Live from April 27 to May 24, the experience rewards those who keep coming back and staying engaged through the cricket season.

Easy to access and designed for seamless navigation, participants can visit AlmondWin.com on their mobile phones during live cricket matches and register using a few basic details with OTP verification - no app download required. Once logged in, users enable camera access to enter an augmented reality experience that blends their surroundings with virtual elements. For any queries along the way, users can easily refer to the detailed FAQs available on AlmondWin.com.

Timed to sync with live cricket matches, the experience comes alive as participants move their phone to spot virtual almonds appearing around them, during key match moments. Whether it’s a six, a sharp catch or a game-changing play, users can jump in and participate by tapping on almonds appearing on their screen. Golden almonds surface during moments such as boundaries, catches or milestones, while silver almonds appear throughout the match. Each almond tapped adds to the participant’s score and unlocks quick, bite-sized almond benefits, making every interaction both engaging and informative.

Participants can return across multiple live cricket matches to build their scores and complete their almond benefits collection. Weekly leaderboards reset to give more participants a chance to win, while overall scores accumulate across the contest period, rewarding consistent engagement. Top weekly performers stand a chance to win tickets to popular cricket matches, while the highest overall scorers who complete their benefits collection, become eligible for the grand prize – tickets to the finals.

Extending beyond live match moments, the experience encourages participants to share their progress on social media, turning engagement into social currency. Timely reminders and WhatsApp nudges help participants stay connected and continue their journey through the contest.

With ‘Superfood for a Super You’ California Almonds creates a unique, immersive campaign for fans to engage with cricket in a whole new way, while reinforcing the role of almonds as a powerful everyday superfood. This season, it’s not just about watching the match – it’s about being a part of every super moment.

For more information, visit AlmondWin.com or follow California Almonds on Instagram, Facebook and YouTube.

Almonds from California are a natural, wholesome and quality food. The Almond Board of California promotes almonds through its research-based approach to all aspects of marketing, farming and production on behalf of the more than 7,600 almond growers and processors in California, many of which are multi-generational family operations. Established in 1950 and based in Modesto, California, the Almond Board of California is a non-profit organisation that administers a grower-enacted Federal Marketing Order under the supervision of the United States Department of Agriculture. For more information on the Almond Board of California or almonds, visit www.almonds.in   

Lilly Supports Haryana State-FDA Action Against Counterfeit Medicines

* Reiterates Importance of Procurement Through Authorised Channels on Valid Prescription

* Patient safety is, and will always remain, Lilly’s highest priority

Eli Lilly and Company (India) commends the actions taken by the Haryana drug control authority in addressing counterfeit products falsely bearing the Mounjaro® (tirzepatide) brand name that were recently seized in Gurugram, Haryana. These seized counterfeit products were not manufactured by Lilly and did not originate from Lilly’s authorised and verified supply chain. Following the diligent investigation by the authority, most of the counterfeit products identified have been recovered. In line with directions issued by the authority, the supply of genuine Lilly product through authorised distributors and licensed pharmacies continues without interruption.

“We recognise the efforts of the Haryana regulatory authority in addressing counterfeit medicines and supporting measures aimed at protecting patient safety.” said Winselow Tucker, President and General Manager, Eli Lilly and Company (India). “Lilly takes any act of counterfeiting very seriously. Counterfeit products are not manufactured under approved quality controls and may pose significant risks to patient safety and public health. We will continue to take steps to protect patients from the risks of counterfeit and other unsafe products worldwide, including working with regulators and law enforcement. We urge patients to procure Lilly products only through authorised distributors or licensed pharmacies, and on a valid prescription. Further, we want to clarify that Lilly’s patented tirzepatide molecule is marketed in India under two brand names — Mounjaro® and Yurpeak®.”

Counterfeit products may look very similar to genuine Lilly medicines. Patients, caregivers, and healthcare professionals are advised to remain vigilant. Suspected counterfeit medicines may include:

· Products obtained from unauthorized or unlicensed sources.

· Packaging that appears tampered with or damaged.

· Missing batch number, expiry date, or manufacturer details.

· Packaging that looks inconsistent with approved product packaging, including misspellings, unfamiliar logos, or different labels.

The below images show authentic Mounjaro® packaging and examples of fake packaging on counterfeit products recently seized by the Haryana FDA. The cartons for the 5 mg dose strength are shown, but the highlighted differences exist on the counterfeit cartons for all dose strengths.

To report suspected falsified medicines or to identify authorized Lilly distributors or pharmacies, please contact Lilly India's toll-free helpline at 1800 123 0021 or write to us at mailbox_in-gps@lilly.com. 

About Lilly

Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com/in, or follow us on Facebook, Instagram, and LinkedIn.